These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17724355)

  • 21. Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.
    Fagnoni P; Limat S; Chaigneau L; Guardiola E; Briaud S; Schmitt B; Merrouche Y; Pivot X; Woronoff-Lemsi MC
    Support Care Cancer; 2006 Oct; 14(10):1030-7. PubMed ID: 16802128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer.
    Adamson JW; Ludwig H
    Oncology; 1999; 56(1):46-53. PubMed ID: 9885377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comments on Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
    Sullivan SD
    Curr Med Res Opin; 2004 Sep; 20(9):1461; author reply 1462-3. PubMed ID: 15487107
    [No Abstract]   [Full Text] [Related]  

  • 24. Why treat anemia in the preoperative period of joint replacement surgery with erythropoietin? IMPACT consults. Proceedings of the 2nd Annual Cleveland Clinic Perioperative Medicine Summit.
    Kumar A; Dimov V
    Cleve Clin J Med; 2006 Sep; 73 Electronic Suppl 1():S13-5. PubMed ID: 17019750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease.
    Papatheofanis F; Bookhart BK; Muser E; Piech CT
    J Occup Environ Med; 2008 May; 50(5):584-9. PubMed ID: 18469628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comments on Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
    Vanscoy GJ
    Curr Med Res Opin; 2004 Sep; 20(9):1459-60; author reply 1462-3. PubMed ID: 15383195
    [No Abstract]   [Full Text] [Related]  

  • 27. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
    Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
    J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Epoetin alfa on hemostasis in chronic renal failure.
    Tang WW; Stead RA; Goodkin DA
    Am J Nephrol; 1998; 18(4):263-73. PubMed ID: 9653828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A star rises, another fades.
    Neumann ME
    Nephrol News Issues; 2013 Jul; 27(8):8. PubMed ID: 23926618
    [No Abstract]   [Full Text] [Related]  

  • 30. Epoetin alfa for treatment of anemia in HIV-infected patients: past, present, and future.
    Henry DH; Volberding PA; Leitz G
    J Acquir Immune Defic Syndr; 2004 Oct; 37(2):1221-7. PubMed ID: 15385728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Epoetin alfa: recent strategies of use].
    Tumori; 1997; 83(6):975-8. PubMed ID: 9537918
    [No Abstract]   [Full Text] [Related]  

  • 32. Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Lefebvre P; Vekeman F; Cremieux PY
    Ann Pharmacother; 2010 Mar; 44(3):595; author reply 595-6. PubMed ID: 20179253
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
    Glaspy J; Bukowski R; Steinberg D; Taylor C; Tchekmedyian S; Vadhan-Raj S
    J Clin Oncol; 1997 Mar; 15(3):1218-34. PubMed ID: 9060566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New York University Medical Center's pilot "Epo-Depot" program: a win-win for patients and health care.
    Smith D; Delmore B
    J Assoc Nurses AIDS Care; 2004; 15(6):23-30. PubMed ID: 15538014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B
    Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.
    Crouch Z; DeSantis ER
    Am J Health Syst Pharm; 2009 Jul; 66(13):1180-5. PubMed ID: 19535656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Focus on epoetin: key findings of mini-sessions.
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):69-75. PubMed ID: 9671335
    [No Abstract]   [Full Text] [Related]  

  • 39. Erythropoietic therapy: cost efficiency and reimbursement.
    Jaspan D
    Am J Health Syst Pharm; 2007 Aug; 64(16 Suppl 11):S19-29. PubMed ID: 17687067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of epoetin alfa in chemotherapy-associated anemia.
    Jilani SM; Glaspy JA
    Semin Oncol; 1998 Oct; 25(5):571-6. PubMed ID: 9783596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.